In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

Tardive dyskinesia is not typically reversible, but on rare occasions, it can be if caught early and treated immediately. Tardive dyskinesia (TD) is a medication-induced movement disorder involving ...

PLANE SAFELY. ANDRE: MAY IS MENTAL HEALTH AWARENESS MONTH AND TONIGHT, WE ARE HIGHLIGHTING A CONDITION THATAN C BE CAUSED BY TAKING CERTAIN ANTICLOTTING -- ANTIPSYCHOTIC MEDICATIONS. IT’S CALLED ...

—A Q&A with Joseph P. McEvoy, MD, Case Distinguished Chair in Psychotic Disorders and Professor, Medical College of Georgia, Augusta University Dr. McEvoy enjoys spending time with patients and does ...

Tardive dyskinesia is a disorder causing uncontrolled movements in the face and body that can be a side effect of prescription drugs including antipsychotics, antidepressants, and more. Tardive ...

Some studies suggest vitamin E may help ease symptoms of tardive dyskinesia — but how strong is the evidence, and what does it really tell us? Note: The U.S. Food and Drug Administration (FDA) does ...

A 36-year-old man with a diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), was referred to a psychiatry clinic for severe, ...

This story also appeared on Everyday Heath's network site BP Hope. The U.S. Food and Drug Administration (FDA) has approved a new sprinkle formulation of valbenazine (Ingrezza) for individuals with ...

This was a prospective cohort study examining the incidence rate of tardive dyskinesia (TD) among 352 outpatients receiving atypical and/or typical antipsychotic medications at a community mental ...

New draft guidelines on the definition of new active substances don’t apply to deutetrabenazine, the European drug regulator ...